PCRX Q2 2024 Earnings — Pacira BioSciences, Inc. Revenue & Financial Results | Market Cap Arena

PCRXPacira BioSciences, Inc.

$971M

Q2 2024 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$178M+5.0% YoY

Gross Profit

$134M75.1% margin

Operating Income

$28M15.9% margin

Net Income

$19M10.6% margin

EPS (Diluted)

$0.39

QoQ Revenue Growth

+6.5%

Cash Flow

Operating Cash Flow

$53M

Free Cash Flow

$52M

Stock-Based Comp.

$13M

Balance Sheet

Total Assets

$1.6B

Total Liabilities

$768M

Stockholders' Equity

$879M

Cash & Equivalents

$247M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$178M	$169M	+5.0%
Gross Profit	$134M	$121M	+10.3%
Operating Income	$28M	$40M	-29.2%
Net Income	$19M	$26M	-26.7%

Revenue Segments

Product

$176M51%

EXPAREL

$137M39%

ZILRETTA

$31M9%

Bupivacaine Liposome Injectable Suspension

$3M1%